Catarina Resende Oliveira
Overview
Explore the profile of Catarina Resende Oliveira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cardoso R, Teunissen C, Oliveira C
J Alzheimers Dis
. 2024 Sep;
101(3):731-734.
PMID: 39240643
Biomarkers that accurately identify mild cognitive impairment (MCI) are of greater importance for Alzheimer's disease (AD) management and treatment. On the other hand, blood-based biomarkers are not only more practical...
2.
Ferreira J, Leite-Moreira A, Da Costa-Pereira A, Soares A, Robalo-Cordeiro C, Jeronimo C, et al.
Acta Med Port
. 2023 Feb;
36(5):305-308.
PMID: 36854257
No abstract available.
3.
Carvalho M, Cunha de Eca R, Gomes I, Goncalves M, Lopes A, Lopes D, et al.
Acta Med Port
. 2021 Mar;
34(2):80-83.
PMID: 33641700
No abstract available.
4.
Cardoso R, Lemos C, Oliveiros B, Almeida M, Baldeiras I, Pereira C, et al.
J Alzheimers Dis
. 2020 Oct;
78(2):587-601.
PMID: 33016906
Background: Mild cognitive impairment (MCI) has been considered as a pre-dementia stage, although the factors leading to Alzheimer's disease (AD) conversion remain controversial. Objective: Evaluate whether TOMM40 poly-T (TOMM40' 523)...
5.
Santana I, Baldeiras I, Santiago B, Duro D, Freitas S, Pereira M, et al.
J Alzheimers Dis
. 2018 Mar;
64(s1):S647-S657.
PMID: 29562515
The amyloid cascade hypothesis proposes amyloid-β (Aβ) as the earliest and key pathological hallmark of Alzheimer's disease (AD), but this mandatory "amyloid-first pathway" has been contested. Longitudinal studies of mild...
6.
Baldeiras I, Santana I, Leitao M, Gens H, Pascoal R, Tabuas-Pereira M, et al.
Alzheimers Res Ther
. 2018 Mar;
10(1):33.
PMID: 29558986
Background: Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of underlying Alzheimer's disease (AD) pathology in mild cognitive impairment (MCI). However, CSF biomarker-based classification often results in...
7.
Candeias E, Sebastiao I, Cardoso S, Carvalho C, Santos M, Oliveira C, et al.
Mol Neurobiol
. 2017 Jun;
55(5):4030-4050.
PMID: 28573460
Type 2 diabetes (T2D) is a modern socioeconomic burden, mostly due to its long-term complications affecting nearly all tissues. One of them is the brain, whose dysfunctional intracellular quality control...
8.
Oliveira C, Mota-Pinto A, Rodrigues V, Alves C
Acta Med Port
. 2017 May;
30(4):293-301.
PMID: 28555555
Introduction: Aging is an inevitable process that has a social impact in the forecoming decades, and it will present a great challenge regarding public health. An efficient health system requires...
9.
Herukka S, Simonsen A, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al.
Alzheimers Dement
. 2017 Mar;
13(3):285-295.
PMID: 28341066
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β, tau, and phosphorylated tau in the...
10.
Simonsen A, Herukka S, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al.
Alzheimers Dement
. 2017 Mar;
13(3):274-284.
PMID: 28341065
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β, tau, and phosphorylated tau in the...